20 research outputs found
Recommended from our members
The upgrade of the Brookhaven Linac Isotope Producer (BLIP) and the BNL Linac
An upgrade project was recently completed on the 200 MeV H{sup -} linac and the Brookhaven Linac Isotope Producer (BLIP) in order to improve radioisotope production capacity and reliability. The average beam current has increased from 60 {mu}A to 150 {mu}A. The increased average current is the result of increases in peak current, from 25 mA to 37 mA, pulse repetition rate, from 5 to 7.5 Hz, and pulse width, from 500 to 530 ps. To achieve this performance the 35 keV, 750 keV and 200 MeV beam transport were improved, the RF transmission lines and RF power supplies replaced. Improvements to the linac control system, and the optics and vacuum system of the 200 MeV transport were implemented. A BLIP the target cooling system was upgraded to 35 kW and automated, the targets, and target mechanical systems replaced with a more robust design, and the control system upgraded. With these enhancements BLIP is ready to address the lack of availability of accelerator produced medical and research isotopes
Recommended from our members
Recent Radioisotope Developments at BNL
This presentation discusses recent radioisotope developments at Brookhaven National Laboratory (BNL)
Recommended from our members
Criteria for the selection of radionuclides for tumor radioimmunotherapy
The potential of utilizing monoclonal antibodies as carriers of radionuclides for the selective destruction of tumors (radioimmunotherapy, RIT) has stimulated much research activity. From dosimetric and other considerations, the choice of radiolabel is an important factor that needs to be optimized for maximum effectiveness of RIT. This paper reviews and assesses a number of present and future radionuclides that are particularly suitable for RIT based on the various physical, chemical, and biological considerations. Intermediate to high-energy beta emitters' (with and without gamma photons in their emission) are emphasized since they possess a number of advantages over alpha and Auger emitters. Factors relating to the production and availability of candidate radiometals as well as their stable chemical attachment to monoclonal antibodies are discussed. 34 refs., 4 tabs
Recommended from our members
New cholescintigraphic agent: ruthenium-97-DISIDA
These studies demonstrate the first application of Ru-97-DISIDA in human subjects. High quality images were obtained. Scintigraphic findings in patients with hepatobiliary disorders were consistent with the biodistribution data obtained in experinmental animals and with other imaging procedures and clinical findings. Administration of Ru-97-DISIDA I.V. and of a solid test meal labeled with Tc-99m-Sulfur Colloid allowed simulateneous detection and quantification of deodenogastric reflux and determination of the gastric emptying rate. This represents an advantage as compared to the currently used techniques which necessitate two separate studies if a solid meal is used, or would mandate a liquid meal for a simultaneous study. The excellent nuclear decay characteristics of Ru-97 (tl/2 69.6 h, gamma 216 keV, 86%, no betas) permit delayed study of the hepatobiliary system with considerably less radiation exposure than I-131 Rose Bengal and with a marked improvement in image quality. 5 refs., 3 figs., 3 tabs